KEYTRUDA COST - AN OVERVIEW

Assessment Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: In combination with chemotherapy, for that therapy of Grownup people with locally recurrent unresectable or metastatic triple-adverse breast cancer who may have not been given prior chemotherapy for metastatic ailment and whose tumours Convey programmed cell death-